Availability of Data and Material
The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.
Conflicts of Interest
The authors have no potential conflicts of interest to disclose.
Author Contributions
Conceptualization: all authors. Data curation: Nilifer Gürbüzer. Methodology: Nilifer Gürbüzer, Mustafa Can Güler. Formal analysis: Nilifer Gürbüzer, İbrahim Hakkı Tör. Investigation: Nilifer Gürbüzer. Writing—original draft: Nilifer Gürbüzer. Writing—review & editing: Nilifer Gürbüzer, Mustafa Can Güler.
Funding Statement
None
Patient group (N=76) | Control group (N=70) | Chi-square | p | |
---|---|---|---|---|
Marital status | 5.488 | 0.067 | ||
Married | 43 (56.6) | 37 (52.9) | ||
Single | 28 (36.8) | 33 (47.1) | ||
Widowed, divorced, living apart | 5 (6.6) | 0 (0.0) | ||
Occupation | 34.859 | <0.001* | ||
Unemployed | 41 (53.9) | 14 (20.0) | ||
Private sector employee | 29 (38.2) | 21 (30.0) | ||
Public employee | 6 (7.9) | 35 (50.0) | ||
Educational status | 39.327 | <0.001* | ||
Primary school | 42 (55.3) | 9 (12.9) | ||
High school | 32 (42.1) | 38 (54.2) | ||
University | 2 (2.6) | 23 (32.9) | ||
Smoking | 6.043 | 0.014* | ||
Yes | 58 (76.3) | 39 (55.7) | ||
No | 18 (23.7) | 31 (44.3) | ||
Alcohol consumption | 0.078 | 0.780 | ||
Yes | 17 (22.4) | 18 (25.7) | ||
No | 59 (77.6) | 52 (74.3) |
Patient group (N=76) | Control group (N=70) | t, Z | p | Effect size | |
---|---|---|---|---|---|
BMI (kg/m2) | 24.00±2.85 | 25.14±1.74 | -2.953* | 0.004* | 0.482 |
Leukocyte (109/L) | 8.60±2.38 | 7.26±1.32 | 4.206* | <0.001* | 0.696 |
Plt (109/L) | 295.25±64.52 | 258.37±44.81 | 4.026* | <0.001* | 0.711 |
MPV (fL) | 9.99±.93 | 10.20±0.67 | -1.603* | 0.111 | |
PCT (%) | 0.29±0.06 | 0.27±0.04 | 3.176* | 0.002* | 0.392 |
Neutrophil (109/L) | 5.08±1.87 | 3.97±.83 | 4.215* | <0.001* | |
Lymphocyte (109/L) | 2.50±.68 | 2.49±0.56 | -0.015* | 0.988 | |
Monocyte (109/L) | 0.69±0.21 | 0.59±0.14 | 3.231* | 0.002* | 0.560 |
Basophil (109/L) | 0.04±0.04 | 0.05±0.09 | -0.354 | 0.723 | |
NLR | 2.24±1.07 | 1.64±0.43 | -3.269 | 0.001* | |
PLR | 127.97±39.10 | 108.62±31.64 | -3.174* | 0.004* | 0.483 |
MLR | 0.29±.012 | 0.24±0.07 | -2.613 | 0.009* | |
BLR | 0.02±0.02 | 0.01±0.01 | -0.643 | 0.520 | |
SII (109/L) | 630.22±301.53 | 423.12±135.56 | 5.422* | <0.001* | 0.885 |
Monocyte/HDL rate | 0.02±0.01 | 0.01±0.004 | -4.800 | <0.001* | |
CRP (mg/L) | 7.21±9.62 | 1.28±1.19 | -5.663 | <0.001* |
Values are presented as mean±standard deviation unless otherwise indicated. Effect Size=Cohen’s d (0.2: small, 0.5: medium, and 0.8: large effect sizes).
BMI, body mass index; t, independent samples t-test; Z, Mann–Whitney U test; Plt, platelet; MPV, mean platelet volume; PCT, plateletcrit; NLR, neutrophil/lymphocyte rate; PLR, platelet/lymphocyte rate; MLR, monocyte/lymphocyte rate; BLR, basophil/lymphocyte rate; SII, systemic immune inflammation index; HDL, high-density lipoprotein; CRP, C-reactive protein
SII, systemic immune inflammation index; BMI, body mass index; Plt, platelet; MPV, mean platelet volume; PCT, plateletcrit; NLR, neutrophil/lymphocyte rate; PLR, platelet/lymphocyte rate; MLR, monocyte/lymphocyte rate; BLR, basophil/lymphocyte rate; HDL, high-density lipoprotein; CRP, C-reactive protein
Model |
Coefficients† |
||||||
---|---|---|---|---|---|---|---|
Unstandardized coefficients |
Standardized coefficients |
t | p |
95% confidence interval for B |
|||
B | SE | Beta | Lower | Upper | |||
1 (constant) | 883.976 | 307.395 | 2.876 | 0.005 | 271.047 | 1,496.905 | |
Age | 0.681 | 4.139 | 0.018 | 0.165 | 0.870 | -7.571 | 8.933 |
BMI | -16.792 | 11.572 | -0.159 | -1.451 | 0.151 | -39.866 | 6.283 |
Methamphetamine use duration | -1.935 | 2.077 | -0.103 | -0.932 | 0.355 | -6.076 | 2.206 |
Daily methamphetamine intake | 165.53 | 47.939 | 0.389 | 3.453 | 0.001* | 69.940 | 261.115 |